NextCure’s NC318 data shines light on SIGLEC15 as next hot IO target

Phase I data from a cohort of NSCLC patients treated with NextCure’s NC318 suggest the SIGLEC15-targeted mAb could be the next immunotherapy to rival the single agent efficacy of PD-1 and PD-L1 inhibitors.

The data drove shares of NextCure Inc. (NASDAQ:NXTC) up $65.79 (248%) to $92.22, giving the company a market cap of $2.1 billion. The stock is now trading at six times the offering price from the company’s May IPO...